pTau217: Providing critical Alzheimer's diagnosis with key biomarker data
3 October 2024
Break through with powerful insights
Every 3.2 seconds, someone globally is diagnosed with Alzheimer’s. pTau217—Labcorp’s simple and highly accurate blood-based test—offers clear answers to accelerate new, needed therapies.
Latest content on neurological biomarker-driven development
Press release
pTau217 blood biomarker test accelerates the path to diagnosis of Alzheimer's disease and supports clinical trials.
Info sheet
See how your breakthrough can reach the right patients with biomarker-driven Alzheimer’s therapy development solutions.
Neurology
Expedite delivery of your therapies to address neurodegenerative disorders with industry-leading testing and trial support.
Biomarker solution center
Leverage the benefits of a biomarker strategy—including 3x greater probability of successful transition from Phase I to regulatory approval.